報價延遲最少15分鐘:2024/12/24 13:48 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.9261 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.07/-1.00
|
|
企業價值
29.70M
|
| 資產負債 |
|
每股賬面淨值
0.18
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 13:48 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need. |